Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction

Christopher P Smith; George T Somogyi; Michael B Chancellor

doi:10.1007/s11934-002-0081-9

Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction

Curr Urol Rep. 2002 Oct;3(5):382-7. doi: 10.1007/s11934-002-0081-9.

Authors

Christopher P Smith¹, George T Somogyi, Michael B Chancellor

Affiliation

¹ Department of Urology, University of Pittsburgh School of Medicine, 700 LS Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA.

PMID: 12354347
DOI: 10.1007/s11934-002-0081-9

Abstract

Botulinum toxin (BTX) is the most lethal naturally occurring toxin known to mankind. Why, then, would an urologist want to use this agent to poison the bladder or urethral sphincter? This article reviews the mechanisms underlying the effects of BTX treatment, summarizes the current usage of this agent within the urologic community, and provides perspectives on future targets of this therapy.

Publication types

Review

MeSH terms

Anti-Dyskinesia Agents / pharmacology
Anti-Dyskinesia Agents / therapeutic use*
Botulinum Toxins / pharmacology
Botulinum Toxins / therapeutic use*
Forecasting
Humans
Neurons, Afferent / drug effects
Urethra / drug effects
Urethra / innervation
Urinary Bladder / drug effects
Urinary Bladder / innervation
Urinary Bladder, Neurogenic / drug therapy*

Substances

Anti-Dyskinesia Agents
Botulinum Toxins